4.1 Review

HIV-1 and the immune response to TB

Journal

FUTURE VIROLOGY
Volume 8, Issue 1, Pages 57-80

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/FVL.12.123

Keywords

antiretroviral therapy; ART; diagnosis; HIV; immunity; immunopathology; TB; TB-associated immune reconstitution inflammatory syndrome; TB-IRIS; tuberculosis

Categories

Funding

  1. Wellcome Trust [084323, 087537, 088316, 094000, 098316, 081667]
  2. MRC (UK) [U.1175.02.002.00014.01]
  3. EDCTP [IP.07.32080.002]
  4. European Union [PIRSES-GA-2011-295214]
  5. Fogarty International Center
  6. NIH [NIH/FIC 1U2RTW007373-01A1, U2RTW007370]
  7. FOGARTY INTERNATIONAL CENTER [U2RTW007373, U2RTW007370] Funding Source: NIH RePORTER

Ask authors/readers for more resources

TB causes 1.4 million deaths annually. HIV-1 infection is the strongest risk factor for TB. The characteristic immunological effect of HIV is on CD4 cell count. However, the risk of TB is elevated in HIV-1 infected individuals even in the first few years after HIV acquisition and also after CD4 cell counts are restored with antiretroviral therapy. In this review, we examine features of the immune response to TB and how this is affected by HIV-1 infection and vice versa. We discuss how the immunology of HIV-TB coinfection impacts on the clinical presentation and diagnosis of TB, and how antiretroviral therapy affects the immune response to TB, including the development of TB immune reconstitution inflammatory syndrome. We highlight important areas of uncertainty and future research needs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available